P-135 Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress — D. Li (2021) | RDL Network
Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Max W. Sung, Ari David Baron, Masatoshi Kudo, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, K. G Mamontov, Tim Meyer, Kalgi Mody, Tomoki Kubota, Corina E. Dutcus, Kenichi Saito, Abby B. Siegel, Leonid Dubrovsky, Josep M. Llovet
Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Andrew X. Zhu, Max W. Sung, Ari David Baron, Takuji Okusaka, Masahiro Kobayashi, H. Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Leonid Dubrovsky, Josep M. Llovet
Josep M. Llovet, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Gianluca Masi, Mariusz Kwiatkowski, Ho Yeong Lim, Jee Hyun Kim, В. В. Бредер, Hiromitsu Kumada, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Anran Wang, Kalgi Mody, Corina E. Dutcus,
Andrew X. Zhu, Josep M. Llovet, Masahiro Kobayashi, Masafumi Ikeda, Marc Pracht, Max W. Sung, Ari David Baron, Masatoshi Kudo, Tim Meyer, Takuji Okusaka, Hiromitsu Kumada, Shuichi Kaneko, Taisuke Hoshi, Kenichi Saito, Shuyu Dan Li, Yasuhiro Funahashi, Yukinori Minoshima, Leonid Dubrovsky, Richard S. Finn
Discussion(0)
No comments yet. Be the first to comment.